ORIGINAL ARTICLE

[Translated article] Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients

I. Belinchón-Romero\textsuperscript{a,*,1}, A. López-Ferrer\textsuperscript{b}, M. Ferrán i Farrés\textsuperscript{c}, R. Rivera-Díaz\textsuperscript{d}, D. Vidal-Sarro\textsuperscript{e}, L. Rodríguez Fernández-Freire\textsuperscript{f}, P. de la Cueva-Dobao\textsuperscript{g}, J. Santos-Juanes\textsuperscript{h}, V. Rocamora-Durán\textsuperscript{i}, V. Martín-Vázquez\textsuperscript{j}, L. Gómez-Labrador\textsuperscript{j}, R. Queiro-Silva\textsuperscript{k,†}, en representación del PURE-4 Study Group

\textsuperscript{a} Departamento de Dermatología, Hospital General Universitario Dr. Balmis de Alicante-ISABIAL, Universidad Miguel Hernández, Alicante, Spain
\textsuperscript{b} Departamento de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
\textsuperscript{c} Departamento de Dermatología, Hospital del Mar, Barcelona, Spain
\textsuperscript{d} Departamento de Dermatología, Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain
\textsuperscript{e} Departamento de Dermatología, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain
\textsuperscript{f} Departamento de Dermatología, Hospital Universitario Virgen del Rocio, Sevilla, Spain
\textsuperscript{g} Departamento de Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain
\textsuperscript{h} Departamento de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Spain
\textsuperscript{i} Departamento de Dermatología, Hospital de Manacor, Palma de Mallorca, Islas Baleares, Spain
\textsuperscript{j} Novartis Farmacéutica S.A., Spain
\textsuperscript{k} División de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain

Received 20 November 2023; accepted 12 February 2024
Available online 28 May 2024

KEYWORDS
Psoriasis;
Psoriatic arthritis;
Screening;
PURE-4;
Referral;
Diagnostic performance

Abstract
Background and objective: Psoriasis often precedes the onset of psoriatic arthritis (PsA), so dermatologists often face the challenge of early identifying signs of PsA in patients with psoriasis. Our aim was to validate the Spanish version of the PURE-4 questionnaire as a screening tool for PsA, evaluate its performance in terms of sensitivity, specificity, feasibility, reliability, and build validity.

Methods: This was a cross-sectional, observational, multicenter trial of adult patients with psoriasis. Initially, patients were assessed by a dermatologist and completed 2 self-administered versions (in print and online) of the PURE-4 questionnaire. Afterwards, the rheumatologist, blinded to the PURE-4 results, assessed the presence/absence of PsA, being the reference to determine the performance of the PURE-4 questionnaire.

DOI of original article: https://doi.org/10.1016/j.ad.2024.02.012
* Corresponding author.
E-mail address: belinchon isa@gva.es (I. Belinchón-Romero).
† These 2 authors contributed equally to this study.

https://doi.org/10.1016/j.ad.2024.05.010
0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Results: A total of 268 patients were included (115 [42.9%] women; mean age, 47.1 ± 12.6). The prevalence of PsA according to rheumatologist diagnosis was 12.7% (34 patients). The mean PURE-4 score for patients with psoriasis diagnosed with PsA was 2.3 ± 1.1, and 1.3 ± 1.3 for patients without PsA (P < .001). The cutoff value ≥ 2 demonstrated the best performance for detecting PsA, with a negative predictive value of 95.1% (95% confidence interval, 90.3-97.6).

Conclusions: The PURE-4 questionnaire demonstrated good performance in detecting PsA, with an optimal cutoff point ≥ 2. This simple tool could facilitate early referral of patients to the rheumatology unit.

© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Methods

Study design and participants

We conducted an observational and multicenter study among 19 Spanish hospitals, with 2 cross-sectional evaluations. Evaluation #1 included psoriatic patients, without a diagnosis of PsA, and was performed by dermatologists and rheumatologists during routine visits. Evaluation #2 included patients without a diagnosis of PsA (in evaluation #1) and was performed by the same rheumatologists 1 year later (±2 months) to determine the presence of PsA (Fig. 1). The results of evaluation #2 are not included in this article.

From November 15 through December 30, 2020, adult patients with psoriasis without a previous diagnosis of PsA who could respond to the PURE-4 questionnaire in paper and electronic formats were recruited. Considering that the probability of finding PsA in patients with moderate-to-severe psoriasis increases, and to ensure a PsA prevalence of 15%, at least, 60% of included patients should have moderate-to-severe psoriasis (Psoriasis Area and Severity Index [PASI] ≥7).12 All participants gave their prior written informed consent before recruitment. The study was approved by Hospital de Bellvitge Ethics Committee (reference PR384/20 [CSI 20/89]) and was conducted following the principles described in the Declaration of Helsinki.

Procedures

The first visit to the dermatologist was followed by an independent visit to the rheumatologist (ideally, on the same day, or within 4 weeks following the dermatologist’s visit). At the time of inclusion, demographic and clinical data were recorded (see Appendix A, “Supplementary Methods,” in the supplementary data), and patients completed the paper version of the PURE-4. Before concluding the visit, the dermatologist provided the patient with the electronic version of the PURE-4 and collected the patient’s opinions and preferences regarding the paper and electronic versions of the questionnaire. Subsequently, the rheumatologist, blinded to the PURE-4 results, assessed the presence/absence of PsA based on the patient’s health history and examination. When additional tests were necessary for the diagnosis of PsA according to clinical practice, an additional 2 months were allowed for confirmation purposes.

Figure 1  Study schematic.

*When additional tests were required for the diagnosis of PsA according to clinical practice, an additional 2 months were allowed to confirm the diagnosis of PsA.

Dx, diagnosis; PsA, psoriatic arthritis.

PURE-4 Questionnaire

The PURE-4 questionnaire consists of 4 questions with affirmative or negative answers about signs of dactylitis, inflammatory heel pain, bilateral buttock pain, and peripheral joint pain with inflammation before the age of 50 (see Appendix A, Figure S1 of the supplementary data). Each positive response scores 1 point, with the maximum score being the sum of “Yes” responses (0 to 4 points).10 An electronic version of the PURE-4 questionnaire in Spanish was also evaluated, supported by a chatbot or virtual assistant, with information and images explaining the meaning of the items.

Study outcomes

The performance of the Spanish paper version of the PURE-4 questionnaire was examined, with the clinical diagnosis being confirmed by the rheumatologist as the reference. Patient perceptions (simple, quick, comfortable, and useful) of the paper and electronic versions were compared using a visual analog scale from 0 up to 10, as well as patient preferences between both versions.

Data analysis

Data are expressed as mean ± standard deviation (or median and interquartile range) for quantitative variables and as frequencies and percentages for categorical variables. Comparisons between participants with and without PsA were made using the Student’s t-test, Fisher’s exact test, and the Mantel-Haenszel test, as appropriate. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to evaluate the performance of PURE-4 in detecting PsA, and validity, sensitivity, specificity, positive predictive value, negative predictive value, and Youden’s index were analyzed to find the optimal cutoff value for patient classification. Additional validation tests are described in Appendix A, “Supplementary Methods” of the supplementary data. The intraclass correlation coefficient (ICC) was used to assess internal consistency between paper and electronic versions of the questionnaire. Statistical analyses were performed using SAS software version 7.15.
Table 1  Demographic and clinical characteristics of all patients with psoriasis and those with and without PsA.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall population (N = 268)</th>
<th>Diagnosed with PsA (N=34)</th>
<th>Without PsA Diagnosis (N=223)*</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>115 (42.9%)</td>
<td>14 (41.2%)</td>
<td>96 (43.0%)</td>
<td>0.837</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>47.1 (12.6)</td>
<td>50.8 (10.0)</td>
<td>46.3 (12.9)</td>
<td>0.039</td>
</tr>
<tr>
<td><strong>Educational level, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic literacy</td>
<td>4 (1.8%)</td>
<td>1 (4.2%)</td>
<td>2 (1.1%)</td>
<td>0.570</td>
</tr>
<tr>
<td>Primary level</td>
<td>36 (16.6%)</td>
<td>5 (20.8%)</td>
<td>29 (15.8%)</td>
<td></td>
</tr>
<tr>
<td>Secondary level</td>
<td>78 (35.9%)</td>
<td>7 (29.2%)</td>
<td>66 (35.9%)</td>
<td></td>
</tr>
<tr>
<td>Higher education</td>
<td>99 (45.6%)</td>
<td>11 (45.8%)</td>
<td>87 (47.3%)</td>
<td></td>
</tr>
<tr>
<td><strong>Years since diagnosis, mean (SD)</strong></td>
<td>18.6 (12.9)</td>
<td>20.2 (14.1)</td>
<td>18.3 (12.9)</td>
<td>0.514</td>
</tr>
<tr>
<td><strong>PASI score, mean (SD)</strong></td>
<td>7.2 (5.1)</td>
<td>8.4 (5.3)</td>
<td>7.0 (5.0)</td>
<td>0.197</td>
</tr>
<tr>
<td>Mild (PASI &lt; 7), n (%)</td>
<td>111 (41.4%)</td>
<td>11 (31.4%)</td>
<td>95 (42.0%)</td>
<td>0.279</td>
</tr>
<tr>
<td>Moderate-to-severe (PASI ≥ 7), n (%)</td>
<td>157 (58.6%)</td>
<td>24 (68.8%)</td>
<td>131 (58.0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Psoriasis location, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Face</td>
<td>39 (14.6%)</td>
<td>8 (23.5%)</td>
<td>31 (13.9%)</td>
<td>0.145</td>
</tr>
<tr>
<td>Neck</td>
<td>13 (4.9%)</td>
<td>3 (8.8%)</td>
<td>10 (4.5%)</td>
<td>0.282</td>
</tr>
<tr>
<td>Trunk</td>
<td>141 (52.6%)</td>
<td>17 (50.0%)</td>
<td>122 (54.7%)</td>
<td>0.608</td>
</tr>
<tr>
<td>Back</td>
<td>100 (37.3%)</td>
<td>13 (38.2%)</td>
<td>84 (37.7%)</td>
<td>0.949</td>
</tr>
<tr>
<td>Extremities and flexures</td>
<td>214 (79.9%)</td>
<td>23 (67.6%)</td>
<td>175 (78.5%)</td>
<td>0.360</td>
</tr>
<tr>
<td>Difficult-to-treat areas</td>
<td>136 (50.7%)</td>
<td>23 (67.6%)</td>
<td>107 (48.0%)</td>
<td>0.033</td>
</tr>
<tr>
<td>-Palmoplantar psoriasis</td>
<td>25 (18.4%)</td>
<td>6 (26.1%)</td>
<td>18 (16.8%)</td>
<td>0.299</td>
</tr>
<tr>
<td>-Nail psoriasis</td>
<td>62 (45.6%)</td>
<td>11 (47.8%)</td>
<td>49 (45.8%)</td>
<td>0.859</td>
</tr>
<tr>
<td>-Scalp psoriasis</td>
<td>110 (80.9%)</td>
<td>20 (87.0%)</td>
<td>86 (80.4%)</td>
<td>0.460</td>
</tr>
<tr>
<td>Others</td>
<td>15 (5.6%)</td>
<td>1 (2.9%)</td>
<td>13 (5.8%)</td>
<td>0.489</td>
</tr>
<tr>
<td><strong>BSA value (0% to 100%), mean (SD)</strong></td>
<td>8.7 (8.0)</td>
<td>10.3 (7.9)</td>
<td>8.5 (8.0)</td>
<td>0.107</td>
</tr>
<tr>
<td><strong>PGA category, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0. Clearance, no signs of psoriasis</td>
<td>18 (8.5%)</td>
<td>2 (6.3%)</td>
<td>15 (8.6%)</td>
<td>0.165</td>
</tr>
<tr>
<td>1. Almost clear, minimal</td>
<td>40 (18.9%)</td>
<td>3 (9.4%)</td>
<td>35 (20.1%)</td>
<td></td>
</tr>
<tr>
<td>2. Mild</td>
<td>59 (27.8%)</td>
<td>8 (25.0%)</td>
<td>49 (28.2%)</td>
<td></td>
</tr>
<tr>
<td>3. Moderate</td>
<td>72 (34.0%)</td>
<td>12 (37.5%)</td>
<td>60 (34.5%)</td>
<td></td>
</tr>
<tr>
<td>4. Severe</td>
<td>23 (10.8%)</td>
<td>7 (21.9%)</td>
<td>15 (8.6%)</td>
<td></td>
</tr>
<tr>
<td><strong>DLQI, mean (SD)</strong></td>
<td>8.2 (6.7)</td>
<td>10.6 (5.9)</td>
<td>7.8 (6.8)</td>
<td>0.028</td>
</tr>
<tr>
<td><strong>Compliance with CASPAR criteria, n (%)</strong></td>
<td>21 (7.8%)</td>
<td>21 (61.8%)</td>
<td>0 (0.0%)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

BSA, body surface area; CASPAR, Classification Criteria for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; PGA, Physician’s Global Assessment; PsA, psoriatic arthritis; SD, standard deviation.

* The diagnosis of PsA was not assessable in 11 patients at the time of the rheumatologist visit.

Results

Study participants and clinical evaluations

A total of 283 psoriatic patients were recruited; 3 were excluded for having PsA or another rheumatologic condition, and 12 because they did not attend their rheumatology appointment. The final analysis included a total of 268 patients (115 [42.9%] women; mean age, 47.1 ± 12.6). Table 1 shows the demographic and clinical data of patients with and without PsA. The mean PASI score was 7.2 ± 5.1. A total of 238 (88.8%) patients were on active treatment for psoriasis. The mean time between dermatology and rheumatology visits was 1.4 ± 1.6 weeks. In evaluation #1, the prevalence of PsA based on the rheumatologist’s diagnosis was 12.7% (n = 34); it was not possible to confirm or rule out the diagnosis of PsA in 11 patients, even after obtaining additional test results within this period. Overall, the most common psoriasis locations were the extremities and flexural areas (PsA, 85.3% vs non-PsA, 78.5%; p = 0.360), trunk (PsA, 50.0% vs non-PsA, 54.7%; p = 0.608), and difficult-to-treat locations (PsA, 67.6% vs non-PsA, 48.0%; p = 0.033). Information on inflammatory signs, imaging findings, and additional tests is shown in Appendix A, Table S1 of the supplementary data.

Figure 2 illustrates the distribution of current psoriasis treatment among patients with and without PsA. Biological therapy was received by 25.8% of patients with PsA vs 46.0% of patients without PsA (p = 0.035), while topical treatments were used by 61.3% vs 32.8%, respectively (p = 0.002).

Questionnaire responses and screening results

All patients completed the PURE-4 questionnaire on paper. Table 2 shows the mean PURE-4 score among patients
with PsA as $2.3 \pm 1.1$, and $1.3 \pm 1.3$ among patients without a diagnosis of PsA ($p < 0.001$). Peripheral joint pain with inflammation before the age of 50 was the item most frequently answered affirmatively by 137 (51.1%) patients (Fig. 3).

Using the Youden index, the optimal cutoff value was ≥ 2, with the highest percentage of properly classified patients, showing a sensitivity rate of 79.4% (95% confidence interval [CI], 63.2-89.7) and a specificity rate of 61.4% (95%CI, 54.9-67.6%) for detecting PsA (Table 3). A total of 63.8% of patients were classified the same by the PURE-4 questionnaire and the rheumatologist, with a negative predictive value of 95.1%. The ROC curve showed an AUC of 0.729 (95%CI, 0.649-0.809) (Fig. 4), indicating good performance of PURE-4. Patient distribution based on the PURE-4 results is shown in Appendix A, Figure S2 of the supplementary data.

The internal consistency of the PURE-4 questionnaire obtained a Cronbach’s α value of 0.610, indicative of good consistency. Supplementary data (Appendix A, Table S2 of the supplementary data) describes the relationship between the PURE-4 score and the clinical variables evaluated by rheumatologists (dactylitis, enthesis, inflammatory back pain, and peripheral joint pain), all of which were statistically significant ($p < 0.05$). The mean PURE-4 score ($2.19 \pm 1.29$) was significantly higher in patients who met the CASPAR criteria than in those who did not ($1.29 \pm 1.26$; $p = 0.002$). The agreement percentage between both diagnostic criteria (PURE-4 and CASPAR) was 61.4%.

### Discussion

This study was motivated by the need to address the challenge of early recognition of PsA by dermatologists treating psoriatic patients. Based on results, the performance of the PURE-4 questionnaire was slightly better than that reported for other PsA screening tools such as the Psoriatic Arthritis Screening Evaluation (PASE), the Psoriasis Epidemiology Screening Tool (PEST), the Toronto Psoriatic Arthritis Screen (ToPAS), or the CONTEST questionnaire, although diagnostic accuracy shows great heterogeneity across screening tools.

### Table 2  PURE-4 Results in Evaluation #1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall population (N = 268)</th>
<th>Diagnosed with PsA (N=34)</th>
<th>Without PsA Diagnosis (N=223)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>PURE-4 Score, mean (SD)</td>
<td>1.4 (1.3)</td>
<td>2.3 (1.1)</td>
<td>1.3 (1.2)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>PURE-4 Score, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>86 (32.1%)</td>
<td>2 (5.9%)</td>
<td>83 (37.2%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>1</td>
<td>62 (16.6%)</td>
<td>5 (14.7%)</td>
<td>54 (24.2%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>58 (21.6%)</td>
<td>13 (38.2%)</td>
<td>43 (19.3%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>43 (16.8%)</td>
<td>9 (26.5%)</td>
<td>30 (13.5%)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>19 (7.1%)</td>
<td>5 (14.7%)</td>
<td>13 (5.8%)</td>
<td></td>
</tr>
</tbody>
</table>

PsA, psoriatic arthritis; PURE-4, Psoriatic Arthritis Uncluttered Screening Evaluation; SD, standard deviation.
Figure 3  Responses given to each item of the PURE-4.
Dx, diagnosis; PsA, psoriatic arthritis; PURE-4, Psoriatic Arthritis UnclutterRed screening Evaluation. * p < 0.05.

Table 3  Sensitivity and specificity of the PURE-4 questionnaire with different cutoff scores.

<table>
<thead>
<tr>
<th>PURE-4 cutoff scores</th>
<th>Sensitivity (95%CI)</th>
<th>Specificity (95%CI)</th>
<th>PPV (95%CI)</th>
<th>NPV (95%CI)</th>
<th>% Properly classified (95%CI)</th>
<th>Youden's Index (J)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1</td>
<td>94.1 (80.9-98.4)</td>
<td>37.2 (31.1-43.7)</td>
<td>18.6 (13.5-25.1)</td>
<td>97.6 (91.8-99.4)</td>
<td>44.7 (38.8-50.9)</td>
<td>0.31</td>
</tr>
<tr>
<td>≥ 2</td>
<td>79.4 (63.2-89.7)</td>
<td>61.4 (54.9-67.6)</td>
<td>23.9 (17.0-32.5)</td>
<td>95.1 (90.3-97.6)</td>
<td>63.8 (57.8-69.4)</td>
<td>0.41</td>
</tr>
<tr>
<td>≥ 3</td>
<td>41.2 (16.4-57.8)</td>
<td>80.7 (75.0-85.4)</td>
<td>24.6 (15.2-37.1)</td>
<td>90.0 (85.7-93.4)</td>
<td>83.7 (78.6-87.7)</td>
<td>0.22</td>
</tr>
<tr>
<td>≥ 4</td>
<td>14.7 (6.4-30.1)</td>
<td>94.2 (90.3-69.6)</td>
<td>27.4 (12.5-50.9)</td>
<td>87.9 (83.1-91.4)</td>
<td>83.7 (78.6-87.7)</td>
<td>0.09</td>
</tr>
</tbody>
</table>

CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; PURE-4, Psoriatic Arthritis UnclutterRed Screening Evaluation. In bold: optimal cut-off point, with the highest percentage of patients correctly classified.

Figure 4  Receiver Operating Characteristic (ROC) curve of the PURE-4 questionnaire for identifying PsA. AUC, area under the curve; PURE-4, Psoriatic Arthritis UnclutterRed screening Evaluation; Se, sensitivity; Sp, specificity.

The ROC curve analysis showed good negative predictive values for detecting PsA, indicating that the PURE-4 questionnaire is suitable for use as an initial screening tool, albeit with some probability of false positive results. Therefore, patients with a score above the cutoff value (>2) should undergo formal rheumatological examination to verify the diagnosis of PsA, which is consistent with the nature of a screening test. There are several benefits associated with the PURE-4 questionnaire: it is a rapid and useful screening method in busy clinics; it streamlines referral to rheumatology, eventual confirmation of PsA,9 and increases the likelihood of patients receiving appropriate treatment to reduce deterioration in their quality of life.17

In our cohort, the prevalence of PsA was 12.7%, which is similar to the one seen in the validation study conducted by Audureau et al.,16 although they used CASPAR criteria as the reference. Although psoriasis severity and duration seem to increase the risk of developing PsA,18,19 in our study, psoriasis severity was similar between those with and without PsA, except for difficult-to-treat areas, which were more common in those with PsA. Additionally, quality of life, assessed by the Dermatology Life Quality Index, was more affected in patients with PsA. Recent data indicate that biological therapies could also have an impact on the incidence of PsA, decreasing or delaying joint involvement.20,21 Our results showed that patients on biological therapy had a lower frequency of PsA. Nonetheless, actively seeking signs of PsA, at least, once a year and, ideally, every 6 months is advisable,9 regardless of the patient’s treatment or psoriasis severity.

Digital tools can encourage patient self-care and facilitate more effective communication between patients and doctors, improving long-term clinical management.22 In this context, the use of new technologies represents a valuable facilitator for implementing digital screening for PsA.24
allowing more active monitoring of patients with psoriasis. The electronic version of the PURE-4 questionnaire showed high correlation (ICC = 0.963) with the conventional questionnaire. This tool could facilitate the remote detection of joint symptoms, in a simple and quick manner. Since timely treatment can reduce cutaneous symptoms, pain, and subclinical inflammation,\textsuperscript{25,26} an accurate detection method has the potential to change the clinical course of PsA. Earlier intervention can prevent arthritis progression, reduce flares, and thus improve disease control and quality of life.\textsuperscript{27}

The limitations of this study are as follows: although the two modalities of the Spanish version of the PURE-4 questionnaire could be used to facilitate PsA detection, the results are applicable to the Spanish context and may not be generalizable to other countries. Additionally, to minimize selection bias, all participants completed the PURE-4 questionnaire regardless of the presence or absence of PsA signs, albeit without confirmed clinical diagnosis. While this could be perceived as a limitation of the patient flow in dermatology clinics, the present study was designed for PURE-4 validation for early PsA detection following linguistic adaptation.\textsuperscript{11} Therefore, it was established that, at least, 60% of the sample should have moderate-to-severe psoriasis, defined by a PASI \(\geq 7,13\) as moderate-to-severe psoriasis presents a higher risk of developing PsA.\textsuperscript{5} Furthermore, 43% of patients were on biological therapy, which likely reduced PsA-related incidence.\textsuperscript{20-22,28} Another limitation, affecting only the comparison between paper and electronic versions of PURE-4, is that the fact that patients completed both versions in the same visit and order, which may have introduced a recall bias in electronic questionnaire responses. However, this does not have an impact on the main objective of the study, as the paper version was always administered first, eliminating the learning effect.

In conclusion, the Spanish version of the PURE-4 questionnaire has been validated using rigorous methods in terms of sensitivity, specificity, feasibility, and construct validity for PsA screening. The optimal cutoff value was \(\geq 2\), with acceptable internal consistency. Both paper and electronic versions were highly rated by the patients, with similar proportions of patients preferring the paper, electronic, or the two versions.

Therefore, this questionnaire could guide early referral to rheumatology, reducing delay in PsA diagnosis and treatment. This tool should be considered as a supplement for dermatologists when exploring signs and symptoms of PsA in psoriatic patients.

Funding

This study was funded by Novartis Farmacéutica S.A., Spain, following good publication practices (GPP-2022).

Conflicts of interest

Isabel Belinchón Romero has received consultant and/or speaker’s fees and participated in clinical trials sponsored by the following pharmaceutical companies whose therapeutic arsenal includes drugs used to treat psoriasis: Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen, Amgen, Leo-Pharma, Pfizer-Wyeth, BMS, UCB, and MSD.

Ana López-Ferrer has received fees for her participation as a member of scientific committees, consultant and/or speaker’s fees, and research grants or participated in clinical trials sponsored by the following pharmaceutical companies (unrelated to this manuscript though): AbbVie, Almirall, Amgen, Janssen, LEO Pharma, MSD, Eli Lilly, Novartis, and UCB Pharma.

Marta Ferrán i Farrés has received consultant and/or speaker’s fees and participated in clinical trials sponsored by the following pharmaceutical companies: Janssen Pharmaceuticals Inc, Eli Lilly, Novartis, Pfizer-Wyeth, MSD, AbbVie, Celgene, and Almirall SA.

Raquel Rivera Díaz has received consultant and/or speaker’s fees and participated in clinical trials sponsored by the following pharmaceutical companies: AbbVie, Almirall SA, Celgene, GSK, Janssen Pharmaceuticals Inc, Eli Lilly, Leo-Pharma, MSD, Novartis, Pfizer-Wyeth, and UCB.

David Vidal Sarro has received consultant and/or speaker’s fees and participated in clinical trials sponsored by the following pharmaceutical companies: AbbVie, Celgene, Eli Lilly, Janssen Pharmaceuticals Inc, Novartis, Gebro Pharma, Leo-Pharma, and UCB.

Lourdes Rodríguez Fernández-Freire has received consultant’s fees and/or fees from the following pharmaceutical companies: AbbVie, Janssen Pharmaceuticals Inc, MSD, Pfizer-Wyeth, Novartis, Celgene, Almirall SA, Eli Lilly, and Leo-Pharma.

Pablo de la Cueva Dobao has received consultant and/or speaker’s fees and participated in clinical trials sponsored by the following pharmaceutical companies: AbbVie, Almirall SA, Astellas Pharma, Biogen Inc., Boehringer Ingelheim, Celgene, Janssen Pharmaceuticals Inc, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, and UCB.

Jorge Santos Juanes has received consultant and/or speaker’s fees from the following pharmaceutical companies: Novartis, Eli Lilly, Janssen Pharmaceuticals Inc, AbbVie, Amgen, and Sanofi.

Vicenc Rocamora Duran has received consultant and/or speaker’s fees from the following pharmaceutical companies: Janssen Pharmaceuticals Inc, Eli Lilly, AbbVie, Almirall, Amgen, and Novartis.

Víctor Martín Vázquez and Lara Gómez Labrador are employees of Novartis in Spain.

Ruben Queiro has received consultant and speaker’s fees and works as project coordinator of the following pharmaceutical companies: Abbvie, Lilly, UCB, Janssen, Pfizer, Amgen, Novartis. Additionally, he has received grants from Janssen, Novartis, and Abbvie.

Acknowledgments

The authors wish to thank Anabel Herrero, PhD, on behalf of Springer Healthcare, for her editorial support and assistance during manuscript writing.
Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ad.2024.05.010.

References


